Clinical Scorecard: Comparative Analysis of Efficacy and Safety Between Variable-Dose and Continuous-Dose Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis

At a Glance

Key Highlights

• Both continuous 200 mg and variable-dose abrocitinib demonstrated long-term efficacy, with specific metrics to be included.
• Continuous dosing was more effective, but variable dosing may minimize adverse events, requiring further elaboration.

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

• M
• o
• n
• i
• t
• o
• r
• f
• o
• r
• a
• d
• v
• e
• r
• s
• e
• e
• v
• e
• n
• t
• s
• ,
• i
• n
• c
• l
• u
• d
• i
• n
• g
• t
• h
• r
• o
• m
• b
• o
• c
• y
• t
• o
• p
• e
• n
• i
• a
• ,
• l
• y
• m
• p
• h
• o
• p
• e
• n
• i
• a
• ,
• a
• n
• d
• h
• y
• p
• e
• r
• l
• i
• p
• i
• d
• e
• m
• i
• a
• ,
• w
• i
• t
• h
• s
• p
• e
• c
• i
• f
• i
• c
• f
• r
• e
• q
• u
• e
• n
• c
• y
• a
• n
• d
• p
• a
• r
• a
• m
• e
• t
• e
• r
• s
• .

Risks

Patient & Prescribing Data

Variable-dose regimens can adapt to disease dynamics while maintaining efficacy, with specific examples of adaptation.

Clinical Best Practices

• adjust_abrocitinib_dosage

Related Resources & Content

• JADE REGIMEN Trial
• JADE EXTEND Trial